Newer cancer therapies—including immune checkpoint inhibitor (ICI) agents, allogeneic stem cell transplantation and hyperthermic intraperitoneal chemotherapy (HIPEC)—are associated with a range of nutritional complications that require careful management, experts said at the ASPEN 2024 Nutrition Science & Practice Conference, in Tampa, Fla.
Nearly a dozen ICIs have been approved by the FDA, with many more in the pipeline. “Checkpoint inhibitors, which target two immune